Seroprotection Status of Hepatitis B Vaccine in Children with Type 1 Diabetes Mellitus

Background:"Type 1 diabetes mellitus [T1DM]" is the most common endocrine disease in the Pediatric population. It has been suggested that T1DM had inadequate immunological response to vaccines, including hepatitis B virus [HBV] vaccine. Aim of the Work:To evaluate the immunological status...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dina Elsharkawy, Hany Abd Elhady El-khaleegy, Saad Mohamed, Gamal Mohamed
Formato:	article
Lenguaje:	EN
Publicado:	Al-Azhar University, Faculty of Medicine (Damietta) 2021
Materias:	seroprotection hepatitis b vaccine type-1 diabetes mellitus Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/bd25e20f301749aaa7ddd3b95d8ead09
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bd25e20f301749aaa7ddd3b95d8ead09
record_format	dspace
spelling	oai:doaj.org-article:bd25e20f301749aaa7ddd3b95d8ead092021-12-02T19:02:51ZSeroprotection Status of Hepatitis B Vaccine in Children with Type 1 Diabetes Mellitus2636-41742682-378010.21608/ijma.2021.81707.1331https://doaj.org/article/bd25e20f301749aaa7ddd3b95d8ead092021-07-01T00:00:00Zhttps://ijma.journals.ekb.eg/article_187697_fc895f4c39c95df2dfdbc56f928fb724.pdfhttps://doaj.org/toc/2636-4174https://doaj.org/toc/2682-3780Background:"Type 1 diabetes mellitus [T1DM]" is the most common endocrine disease in the Pediatric population. It has been suggested that T1DM had inadequate immunological response to vaccines, including hepatitis B virus [HBV] vaccine. Aim of the Work:To evaluate the immunological status against HBV vaccine among children with T1DM, and assess various possible risk factors for immunity failure. Patients and Methods:A comparative cross-sectional study included 60 children [4-10 years] with T1DM [case group], and 60 healthy age- and sex-matched children [control group]. All included children had completed obligatory HBV vaccine. The evaluation of the immunological response was assessed through analysis of antibodies against HBV surface [HBsAB]. Seroprotection status to HBV vaccine was identified as plasma HBsAB of ≥ 10 mIU/ml. Results:The mean duration of T1DM was 2.03 ± 1.73 years. The frequency of immunity failure to HBV vaccine [non-responders; HBsAB < 10 mIU/ml] was 51.7% among the case group, and 28.3% among the control group [P = 0.009]. Risk factors for immunity failure, as evaluated by regression analysis, were older age [P=0.002], and longer duration of T1DM [P=0.023]. Conclusion: Children with T1DM have a reduced level of HBV vaccine seroprotection when compared to the control group. Patients with older age and longer duration of T1DM showed a trend toward non-responding HbsAB titer. Long-term follow-up of responders is recommended to retest the level of immune response.Dina ElsharkawyHany Abd Elhady El-khaleegySaad MohamedGamal MohamedAl-Azhar University, Faculty of Medicine (Damietta)articleseroprotectionhepatitis bvaccinetype-1 diabetes mellitusMedicine (General)R5-920ENInternational Journal of Medical Arts, Vol 3, Iss 3, Pp 1748-1753 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	seroprotection hepatitis b vaccine type-1 diabetes mellitus Medicine (General) R5-920
spellingShingle	seroprotection hepatitis b vaccine type-1 diabetes mellitus Medicine (General) R5-920 Dina Elsharkawy Hany Abd Elhady El-khaleegy Saad Mohamed Gamal Mohamed Seroprotection Status of Hepatitis B Vaccine in Children with Type 1 Diabetes Mellitus
description	Background:"Type 1 diabetes mellitus [T1DM]" is the most common endocrine disease in the Pediatric population. It has been suggested that T1DM had inadequate immunological response to vaccines, including hepatitis B virus [HBV] vaccine. Aim of the Work:To evaluate the immunological status against HBV vaccine among children with T1DM, and assess various possible risk factors for immunity failure. Patients and Methods:A comparative cross-sectional study included 60 children [4-10 years] with T1DM [case group], and 60 healthy age- and sex-matched children [control group]. All included children had completed obligatory HBV vaccine. The evaluation of the immunological response was assessed through analysis of antibodies against HBV surface [HBsAB]. Seroprotection status to HBV vaccine was identified as plasma HBsAB of ≥ 10 mIU/ml. Results:The mean duration of T1DM was 2.03 ± 1.73 years. The frequency of immunity failure to HBV vaccine [non-responders; HBsAB < 10 mIU/ml] was 51.7% among the case group, and 28.3% among the control group [P = 0.009]. Risk factors for immunity failure, as evaluated by regression analysis, were older age [P=0.002], and longer duration of T1DM [P=0.023]. Conclusion: Children with T1DM have a reduced level of HBV vaccine seroprotection when compared to the control group. Patients with older age and longer duration of T1DM showed a trend toward non-responding HbsAB titer. Long-term follow-up of responders is recommended to retest the level of immune response.
format	article
author	Dina Elsharkawy Hany Abd Elhady El-khaleegy Saad Mohamed Gamal Mohamed
author_facet	Dina Elsharkawy Hany Abd Elhady El-khaleegy Saad Mohamed Gamal Mohamed
author_sort	Dina Elsharkawy
title	Seroprotection Status of Hepatitis B Vaccine in Children with Type 1 Diabetes Mellitus
title_short	Seroprotection Status of Hepatitis B Vaccine in Children with Type 1 Diabetes Mellitus
title_full	Seroprotection Status of Hepatitis B Vaccine in Children with Type 1 Diabetes Mellitus
title_fullStr	Seroprotection Status of Hepatitis B Vaccine in Children with Type 1 Diabetes Mellitus
title_full_unstemmed	Seroprotection Status of Hepatitis B Vaccine in Children with Type 1 Diabetes Mellitus
title_sort	seroprotection status of hepatitis b vaccine in children with type 1 diabetes mellitus
publisher	Al-Azhar University, Faculty of Medicine (Damietta)
publishDate	2021
url	https://doaj.org/article/bd25e20f301749aaa7ddd3b95d8ead09
work_keys_str_mv	AT dinaelsharkawy seroprotectionstatusofhepatitisbvaccineinchildrenwithtype1diabetesmellitus AT hanyabdelhadyelkhaleegy seroprotectionstatusofhepatitisbvaccineinchildrenwithtype1diabetesmellitus AT saadmohamed seroprotectionstatusofhepatitisbvaccineinchildrenwithtype1diabetesmellitus AT gamalmohamed seroprotectionstatusofhepatitisbvaccineinchildrenwithtype1diabetesmellitus
_version_	1718377234054512640

Seroprotection Status of Hepatitis B Vaccine in Children with Type 1 Diabetes Mellitus

Ejemplares similares